AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 251 min read$ATEX

After $10M sale, Anterix (ATEX) officer plans more stock selling

Anterix (ATEX) officer Christopher Guttman-McCabe plans to sell 23,439 shares, valued at $2.16M, on 08/25/2026 under Rule 144. He previously sold 122,852 shares for $10.04M in the last 3 months. ATEX has 19.61M common shares outstanding.

Original reporting
stocktitan.net
Published Aug 25, 2026, 8:25 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ATEX
Neutral
medium confidence
Mentioned
$ATEX
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ATEXNeutralLow
01

Why it matters

The disclosed sale adds a modest amount of shares to the market, likely causing limited price movement.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate news could amplify the sale's effect.

Relevance 4/10Novelty 4/10Timing: sale scheduled for 08/25/2026

Background

Form 144 filing discloses insider's planned share sale after exercising stock options.

Company-level read

Ticker impact

$ATEXNeutralMedium confidence
Context

Officer Christopher Guttman-McCabe plans to sell 23,439 shares (~$2.16M) under Rule 144 on 08/25/2026.

Expected impact

Minor downward pressure if the sale is executed quickly.

Evidence & confidence

The sale size is small relative to market cap; impact limited unless market is thin.

Market effects

Sector

Minimal effect on telecom infrastructure sector.

Regional

No regional impact.

Global

None

Counterpoint

What could challenge this read

Insider may be diversifying, not a negative signal.

Key entities

  • Company
    Anterix Inc.

    US-listed telecom infrastructure provider (ticker ATEX).

  • Officer
    Christopher Guttman-McCabe

    Company officer planning the share sale.

Read at source← All news

Related articles

AUG 19
$ATEXMed

Anterix (ATEX) Q1 2027 Earnings Call Transcript

Anterix (ATEX) reported Q1 2027 revenue of $2M, up from $1.4M YoY, with net income of $240K. Operating expenses decreased to $12.9M. The company has $116M in cash, no debt, and $226.7M left for share repurchases. Management highlighted 12 active deals, spectrum clearing progress, and support for SpaceX's FCC proposal. CFO warned of potential higher costs if spectrum clearing is accelerated.

fool.com4 min
AUG 11
$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Anterix Inc. Reports First Quarter Fiscal Year 2027 Results Woodland Park, NJ – August 11, 2026 – Anterix (NASDAQ: ATEX) today announced its first quarter fiscal 2027 results and filed its Form 10-Q for the three months ended June 30, 2026. Financial and Operational Highlights –

SEC EDGAR 8-K6 min
JUN 10
$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2

SEC EDGAR 8-K6 min
AUG 28
$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

yahoo.com3 min
AUG 28
$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi

wisbusiness.com3 min